Derma Sciences sales jump 16 percent | Earnings roundup

March 31, 2011 By MassDevice staff Leave a Comment

MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.

Here’s a quick rundown of a few releases over the past couple days:

Derma Sciences sales jump 16 percent
Derma Sciences Inc. (NSDQ:DSCI) reported losses of $347,198, or 5 cents per diluted share, on sales of $15.3 million during the three months ended Dec. 31, 2010. That compares with profits $843, or less than 1 cent per diluted share, on sales of $13.6 million during the same period in 2009.

Full-year losses were $2.4 million, or 39 cents per share, on sales of $56.5 million. That compares with losses of $1.3 million, or 25 cents per share, on sales of $48.5 million in 2009.
Read more

Bacterin losses widen more than 340 percent
Bacterin International Holdings Inc. (NYSE Amex:BONE) reported losses of $5.5 million, or 15 cents per basic share, on sales of $5.3 million during the three months ended Dec. 31, 2010. That compares with losses of $1.6 million, or 6 cents per basic share, on sales of $2.2 million during the same period in 2009.

Full-year losses were $18.2 million, or 57 cents per share, on sales of $15.4 million. That compares with losses of $4.1 million, or 16 cents per share, on sales of $7.4 million in 2009.
Read more

Response Genetics losses halve
Response Genetics Inc. (NSDQ:RGDX) reported losses of $1.1 million, or 6 cents per basic share, on sales of $6.4 million during the three months ended Dec. 31. That compares with losses of $1.7 million, or 11 cents per diluted share, on sales of $3.4 during the same period in 2009.

Full-year losses were $4.7 million, or 26 cents per share, on sales of $21.3 million. That compares with losses of $9.3 million, or 70 cents per share, on sales of $9.1 million in 2009.
Read more

Nephros losses remain unchanged after small sales bump
Nephros Inc. (OTC:NEPHD) reported losses of $665,000, or 32 cents per diluted share, on sales of $517,000 during the three months ended Dec. 31, 2010. That compares with losses of $483,000, or 25 cents per diluted share, on sales of $792,000 during the same period in 2009.

Full-year losses were $1.9 million, or 93 cents per share, on sales of $2.9 million. That compares with losses of $2.0 million, or $1.06 per share, on sales of $2.7 million in 2009.
Read more

Guided Therapeutics losses ease after sales double
Guided Therapeutics Inc. (OTC:GTHP) reported losses of $280,000, or 1 cent per diluted share, on sales of $1.1 million during the three months ended Dec. 31, 2010. That compares with losses of $1.5 million, or 8 cents per diluted share, on sales of $550,000 during the same period in 2009.

Full-year losses were $4.5 million, or 12 cents per share, on sales of $3.4 million. That compares with losses of $6.4 million, or 38 cents per share, on sales of $1.6 million in 2009.
Read more

Elbit sales push company into the black
Elbit Imaging Ltd. (NSDQ:EMITF) reported profits of $19.5 million on sales of $111.9 million during the year ended Dec. 31, 2010. That compares with losses of $190.6 million on no revenue in 2009.
Read more

Spherix losses ease despite unchanged sales
Spherix Inc. (NSDQ:SPEX) reported losses of $7.7 million, or 43 cents per diluted share, on sales of $1.4 million during the year ended Dec. 31, 2010. That compares with losses of $9.1 million, or 62 cents per diluted share, on sales of $1.4 million in 2009.
Read more

NeurogesX losses double
NeurogesX Inc. (NSDQ:NGSX) reported losses of $12.4 million, or 69 cents per diluted share, on sales of $458,000 during the three months ended Dec. 31, 2010. That compares with losses $5.1 million, or 29 cents per diluted share, on no revenues during the same period in 2009.

Full-year losses were $44.5 million, or $2.51 cents per share, on sales of $688,000. That compares with losses of $21.9 million, or $1.24 per share, on no revenues in 2009.
Read more

New 510(k) boosts iRhythm, Verily efforts for AFib screening
The latest 510(k) clearance for the Verily Study Watch will further the efforts of the Google sister company and iRhythm Technologies (NSDQ:IRTC) to improve atrial fibrillation treatment. Verily — a life science company under Alphabet (NSDQ:GOOGL) — recently received an FDA 510(k) clearance to include an irregular pulse monitor in its Study Watch wearable. “We’ve worked carefully to meet the FDA’s stringent… […]
Argon Medical debuts IVC filter retrieval kits
Argon Medical Devices (Frisco, Texas) said this week that it has launched single-loop and triple-loop retrieval kits for percutaneous removal of inferior vena cava (IVC) filters that are no longer medically required. The kits are indicated for use via a jugular approach and offer the following features: A coil-reinforced outer sheath with the strength needed… […]
NANS 2020: Neuromodulation news you need to know
Neuromodulation devices from companies including Medtronic (NYSE:MDT), Abbott (NYSE:ABT) and SPR Therapeutics are showing promise treating pain. That’s one of the initial takeaways from study results that medical device companies in the neuromodulation space are touting this weekend at NANS 2020 in Las Vegas. NANS is a joint conference of Congress of Neurological Surgeons and the North American Neuromodulation… […]
Injection Molding Principles
Optimizing custom part designs for injection molding requires a thorough understanding of the process and outcomes. In this e-book, you’ll learn about common molding resins, special molding terms you should know, and most importantly, how to optimize your part with undercuts, even walls, drafts, and more. Download this e-book from Xometry to learn more… The […]
GW Plastics expands Vermont manufacturing and tech center
GW Plastics announced that it has completed a $10 million expansion of its Royalton, Vt., manufacturing and technology center. The company said it has added a 30,000 ft2 to the building to accommodate the growth of its thermoplastic injection molding and medical device contract assembly business. The expansion includes a new 13,000 ft2, Class 8… […]
Certain GE Healthcare patient-monitoring devices vulnerable to cyberattack
The federal government and GE Healthcare (NYSE:GE) announced today that the certain of the company’s patient monitoring devices are vulnerable to cyberattack. If attacked, some versions of the Carescape and ApexPro telemetry servers, the Carescape Central Station version 1 and Central Information Center systems could stop monitoring patients, silence alarms or produce unnecessary alarms during… […]
Cardinal Health recalls 9 million surgical gowns, sends hospitals scrambling
Cardinal Health (NYSE:CAH) announced that it is voluntarily recalling 9.1 million surgical gowns produced by an unnamed contract manufacturer after discovering quality issues with the product. The Dublin, Ohio-based company said that some gowns were produced in unapproved locations that did not maintain proper environmental conditions as required by law. Some of the gowns were also… […]
KNF launches compact swing piston pump
KNF Neuberger is touting its NPK 06 swing piston micro gas pumps, designed to deliver high-flow and high-pressure performance in a compact size. The new pumps work well for medical diagnostics, therapy, monitoring, and general compression applications, according to the Trenton, N.J.-based company. NPK 06 measures 1.85” (47mm) wide and can produce free flow up… […]
Heraeus Medical Components and Myant partner on electrical sensing for textiles
Heraeus Medical Components (St. Paul, Minn.) and Toronto-based Myant have entered a partnership enabling Myant to use Heraeus’ Tectitoat for electrical sensing applications in textiles, the companies announced today. Tecticoat is a conductive polymer-based coating that can be applied to textiles to control electrical conductivity, electromagnetic shielding and electrostatic dissipation, making it suitable for integration… […]
Cook Medical’s peripheral artery set debuts in U.S.
Cook Medical recently announced the U.S. launch of its TriForce peripheral crossing set to support vascular obstruction procedures. The TriForce set is designed to be percutaneously introduced into blood vessels to support a wire guide while performing a peripheral intervention, according to the Bloomington, Ind.-based company. This device is also intended for injection of radiopaque… […]
Bayer and Exscientia partner to bring AI to drug discovery
Bayer (ETR:BAYN) announced that it is entering into a collaboration agreement with artificial intelligence drug discovery company Exscientia to identify and optimize novel lead structures for potential drug candidates in treating cardiovascular and oncological diseases. The agreement, announced earlier this month, is slated to see the companies work together on early research projects combining Exscientia’s proprietary… […]